2019 Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 255 pages | ID: 2DE8F05A99BEN
VPAResearch

Abstracts

The global clinical trial report- “2019 Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Wet (Neovascular / Exudative) Macular Degeneration. It presents in-depth analysis of Wet (Neovascular / Exudative) Macular Degeneration clinical trials across markets and companies. The research work is for providing complete understanding into trends in Wet (Neovascular / Exudative) Macular Degeneration.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Wet (Neovascular / Exudative) Macular Degeneration clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Wet (Neovascular / Exudative) Macular Degeneration

The research work is prepared through extensive and continuous research on Wet (Neovascular / Exudative) Macular Degeneration trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Wet (Neovascular / Exudative) Macular Degeneration patients are identified
• The report includes panorama of Wet (Neovascular / Exudative) Macular Degeneration clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Wet (Neovascular / Exudative) Macular Degeneration clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Region
  2.2.2 Average Enrollment of Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Wet (Neovascular / Exudative) Macular Degeneration Treatment, 2019

3. REGION WISE WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION CLINICAL TRIALS

3.1 Asia Pacific Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country
3.2 Europe Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country
3.3 North America Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country
3.4 Middle East and Africa Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country
3.5 South and Central America Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Country

4. WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION CLINICAL TRIAL TRENDS

4.1 Start Year wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials
4.2 Phase wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials
4.3 Trial Status wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials
4.4 Trial Type wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials

5. WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Year
5.2 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Phase
5.3 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Status
5.4 Average Enrollment in Wet (Neovascular / Exudative) Macular Degeneration Trials by Type of Trial

6. COMPANIES PARTICIPATING IN WET (NEOVASCULAR / EXUDATIVE) MACULAR DEGENERATION CLINICAL TRIALS

6.1 Wet (Neovascular / Exudative) Macular Degeneration Trials by Sponsor Type
6.2 Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase
7.2 Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase
7.3 Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase
7.4 Wet (Neovascular / Exudative) Macular Degeneration Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Figure 5: Europe – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Figure 7: North America – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Figure 9: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Phase
Figure 10: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Trial Status
Figure 11: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Type
Figure 12: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Sponsor Type
Figure 13: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials by Leading Sponsors
Figure 14: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Phase
Figure 15: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Trial Status
Figure 16: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Type
Figure 17: Wet (Neovascular / Exudative) Macular Degeneration- Average Enrolment by Type of Sponsors
Figure 18: Wet (Neovascular / Exudative) Macular Degeneration- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Table 5: Europe – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Table 7: North America – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Wet (Neovascular / Exudative) Macular Degeneration Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Phase
Table 15: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Trial Status
Table 16: Wet (Neovascular / Exudative) Macular Degeneration Average Enrollment by Type
Table 17: Wet (Neovascular / Exudative) Macular Degeneration- Average Enrolment by Type of Sponsors
Table 18: Wet (Neovascular / Exudative) Macular Degeneration- Enrolment by Leading Sponsors